CVS Health Corporation (CVS)
NYSE: CVS · Real-Time Price · USD
79.10
-1.26 (-1.57%)
At close: Dec 1, 2025, 4:00 PM EST
79.02
-0.08 (-0.10%)
After-hours: Dec 1, 2025, 7:59 PM EST
CVS Health Revenue
CVS Health had revenue of $102.24B in the quarter ending September 30, 2025, with 7.76% growth. This brings the company's revenue in the last twelve months to $391.69B, up 6.66% year-over-year. In the year 2024, CVS Health had annual revenue of $370.66B with 3.93% growth.
Revenue (ttm)
$391.69B
Revenue Growth
+6.66%
P/S Ratio
0.26
Revenue / Employee
$1,305,633
Employees
300,000
Market Cap
100.41B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 370.66B | 14.03B | 3.93% |
| Dec 31, 2023 | 356.62B | 34.99B | 10.88% |
| Dec 31, 2022 | 321.63B | 30.72B | 10.56% |
| Dec 31, 2021 | 290.91B | 23.00B | 8.59% |
| Dec 31, 2020 | 267.91B | 12.14B | 4.75% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
CVS News
- 16 hours ago - Cornerstone Community Development, Winterwood, CVS Health, and Community Organizations Announce the Prichard Centennial Residential Reveal and Next-Phase Preview - PRNewsWire
- 17 hours ago - Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields - Benzinga
- 18 hours ago - Harrow: Vevye Replaces Xiidra On Tier 1 Formulary At CVS - Seeking Alpha
- 4 days ago - These outperforming stocks are still cheap heading into 2026 - Invezz
- 6 days ago - Abortion pill makers brace for restrictions a year after Trump's election - CNBC
- 7 days ago - Curaechoice Selects CVS Caremark at its PBM - GlobeNewsWire
- 7 days ago - Wall Street Breakfast Podcast: Ubisoft Cracks Next Level With Tencent - Seeking Alpha
- 11 days ago - CVS Health Names David Joyner Chair of the Board of Directors - PRNewsWire